Page 43 - Read Online

Strassheim et al. Vessel Plus 2018;2:29 I http://dx.doi.org/10.20517/2574-1209.2018.44 Page 15 of 22

potential. J Pharmacol Exp Ther 2017;362:186-99.
63. Chen CH, Lin H, Hsu YH, Sue YM, Cheng TH, Chan P, Chen TH. The protective effect of prostacyclin on adriamycin-induced
apoptosis in rat renal tubular cells. Eur J Pharmacol 2006;529:8-15.
64. Chen HH, Chen TW, Lin H. Prostacyclin-induced peroxisome proliferator-activated receptor-alpha translocation attenuates NF-kappaB
and TNF-alpha activation after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2009;297:F1109-18.
65. Kimura TE, Duggirala A, Smith MC, White S, Sala-Newby GB, Newby AC, Bond M. The Hippo pathway mediates inhibition of
vascular smooth muscle cell proliferation by cAMP. J Mol Cell Cardiol 2016;90:1-10.
66. Singh S, Simpson RL, Bennett RG. Relaxin activates peroxisome proliferator-activated receptor gamma (PPARgamma) through a
pathway involving PPARgamma coactivator 1alpha (PGC1alpha). J Biol Chem 2015;290:950-9.
67. Xia J, Yang L, Dong L, Niu M, Zhang S, Yang Z, Wumaier G, Li Y, Wei X, Gong Y, Zhu N, Li S. Cefminox, a dual agonist of
prostacyclin receptor and peroxisome proliferator-activated receptor-gamma identified by virtual screening, has therapeutic efficacy
against hypoxia-induced pulmonary hypertension in rats. Front Pharmacol 2018;9:134.
68. Falcetti E, Flavell DM, Staels B, Tinker A, Haworth SG, Clapp LH. IP receptor-dependent activation of PPARgamma by stable
prostacyclin analogues. Biochem Biophys Res Commun 2007;360:821-7.
69. Idris-Khodja N, Ouerd S, Trindade M, Gornitsky J, Rehman A, Barhoumi T, Offermanns S, Gonzalez FJ, Neves MF, Paradis P, Schiffrin
EL. Vascular smooth muscle cell peroxisome proliferator-activated receptor gamma protects against endothelin-1-induced oxidative
stress and inflammation. J Hypertens 2017;35:1390-401.
70. Harrington LS, Moreno L, Reed A, Wort SJ, Desvergne B, Garland C, Zhao L, Mitchell JA. The PPARbeta/delta agonist GW0742
relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PLoS One
2010;5:e9526.
71. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith
RL. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--
activated receptor gamma. Cancer Prev Res (Phila) 2008;1:349-56.
72. Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, Lee MK, Kim UH, Lee YC. Peroxisome proliferator activated receptor-gamma
modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic
airway disease of mice. J Allergy Clin Immunol 2006;118:120-7.
73. Wang J, Fu X, Yang K, Jiang Q, Chen Y, Jia J, Duan X, Wang EW, He J, Ran P, Zhong N, Semenza GL, Lu W. Hypoxia inducible
factor-1-dependent up-regulation of BMP4 mediates hypoxia-induced increase of TRPC expression in PASMCs. Cardiovasc Res
2015;107:108-18.
74. Wang J, Weigand L, Lu W, Sylvester JT, Semenza GL, Shimoda LA. Hypoxia inducible factor 1 mediates hypoxia-induced TRPC
expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells. Circ Res 2006;98:1528-37.
75. Wang Y, Lu W, Yang K, Wang Y, Zhang J, Jia J, Yun X, Tian L, Chen Y, Jiang Q, Zhang B, Chen X, Wang J. Peroxisome proliferator-
activated receptor gamma inhibits pulmonary hypertension targeting store-operated calcium entry. J Mol Med (Berl) 2015;93:327-42.
76. Chen T, Zhou Q, Tang H, Bozkanat M, Yuan JX, Raj JU, Zhou G. miR-17/20 Controls prolyl hydroxylase 2 (PHD2)/hypoxia-inducible
factor 1 (HIF1) to regulate pulmonary artery smooth muscle cell proliferation. J Am Heart Assoc 2016;5.
77. Gusan S, Anand-Srivastava MB. cAMP attenuates the enhanced expression of Gi proteins and hyperproliferation of vascular smooth
muscle cells from SHR: role of ROS and ROS-mediated signaling. Am J Physiol Cell Physiol 2013;304:C1198-209.
78. Dai Y, Luo W, Chang J. Rho kinase signaling and cardiac physiology. Curr Opin Physiol 2018;1:14-20.
79. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho kinase-mediated
vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007;100:923-9.
80. Zhao L, Sebkhi A, Ali O, Wojciak-Stothard B, Mamanova L, Yang Q, Wharton J, Wilkins MR. Simvastatin and sildenafil combine to
attenuate pulmonary hypertension. Eur Respir J 2009;34:948-57.
81. Yao J, Xiong M, Tang B, Chen G, Liang M, Ma X, Wang Z, Wu Z. Simvastatin attenuates pulmonary vascular remodelling by down-
regulating matrix metalloproteinase-1 and -9 expression in a carotid artery-jugular vein shunt pulmonary hypertension model in rats.
Eur J Cardiothorac Surg 2012;42:e121-7.
82. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM. Inhibition of protein geranylgeranylation and
RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 2002;277:15309-16.
83. Kawasaki Y, Yokobayashi E, Sakamoto K, Tenma E, Takaki H, Chiba Y, Otashiro T, Ishihara M, Yonezawa S, Sugiyama A, Natori Y.
Angiostatin prevents IL-1beta-induced down-regulation of eNOS expression by inhibiting the NF-kappaB cascade. J Pharmacol Sci
2015;129:200-4.
84. Niwano K, Arai M, Koitabashi N, Hara S, Watanabe A, Sekiguchi K, Tanaka T, Iso T, Kurabayashi M. Competitive binding of CREB
and ATF2 to cAMP/ATF responsive element regulates eNOS gene expression in endothelial cells. Arterioscler Thromb Vasc Biol
2006;26:1036-42.
85. Niwano K, Arai M, Tomaru K, Uchiyama T, Ohyama Y, Kurabayashi M. Transcriptional stimulation of the eNOS gene by the stable
prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: close link between PGI2
signal and NO pathways. Circ Res 2003;93:523-30.
86. Steven S, Daiber A, Dopheide JF, Munzel T, Espinola-Klein C. Peripheral artery disease, redox signaling, oxidative stress - Basic and
clinical aspects. Redox Biol 2017;12:787-97.
87. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced
pulmonary hypertension. Circulation 2003;107:3230-5.